Comparative Pharmacology
Head-to-head clinical analysis: MACROTEC versus METASTRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROTEC versus METASTRON.
MACROTEC vs METASTRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable for diagnostic use.
Strontium-89 chloride is a bone-seeking radiopharmaceutical that emits beta radiation. After intravenous administration, it is taken up preferentially by osteoblastic bone metastases, where its beta decay causes DNA damage and cell death in tumor cells.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
Metastron (strontium-89 chloride) is administered intravenously at a dose of 148 MBq (4 mCi) as a single injection.
None Documented
None Documented
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Terminal elimination half-life is approximately 50.5 days (range 20-87 days). Clinical context: due to prolonged retention in bone metastases, radiobiological half-life exceeds physical half-life; therapeutic effect persists for weeks despite declining plasma levels.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Renal excretion of strontium-89; approximately 70% excreted in urine within 48 hours, with the remainder eliminated over weeks via both renal and fecal routes (12-20% fecal).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical